Literature DB >> 8190239

EEG power spectra in Huntington's disease: clinical and neuropsychological correlates.

F W Bylsma1, C E Peyser, S E Folstein, M F Folstein, C Ross, J Brandt.   

Abstract

Quantitative power spectral analysis (PSA) was applied to frontal (F3, F4, F7, F8), temporal (T5, T6), and occipital (O1, O2) EEGs of 16 Huntington's disease (HD) patients and eight healthy control subjects. PSA revealed HD patients' EEGs to be abnormal: (i) raw and percent Alpha power were reduced; (ii) raw and percent Theta power were reduced at F3 and F4; (iii) percent Delta and percent Beta power were increased; (iii) Theta frequency was reduced by approximately 1.0 Hz. Frontal and temporal EEG power measures and decreased EEG amplitude correlated with severity of neurological and cognitive impairment.

Entities:  

Mesh：

Year:  1994        PMID： 8190239     DOI： 10.1016/0028-3932(94)90001-9

Source DB:  PubMed          Journal:  Neuropsychologia        ISSN： 0028-3932            Impact factor:   3.139


  17 in total

1.  Arousal and the control of perception and movement.

Authors:  E Garcia-Rill; T Virmani; J R Hyde; S D'Onofrio; S Mahaffey
Journal:  Curr Trends Neurol       Date:  2016

2.  Corticostriatal dysfunction and glutamate transporter 1 (GLT1) in Huntington's disease: interactions between neurons and astrocytes.

Authors:  Ana María Estrada-Sánchez; George V Rebec
Journal:  Basal Ganglia       Date:  2012-07-01

3.  Blockade of striatal adenosine A2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum.

Authors:  Patrizia Popoli; Annita Pintor; Maria Rosaria Domenici; Claudio Frank; Maria Teresa Tebano; Antonella Pèzzola; Laura Scarchilli; Davide Quarta; Rosaria Reggio; Fiorella Malchiodi-Albedi; Mario Falchi; Marino Massotti
Journal:  J Neurosci       Date:  2002-03-01       Impact factor: 6.167

Review 4.  Neuronal Network Oscillations in Neurodegenerative Diseases.

Authors:  Volker Nimmrich; Andreas Draguhn; Nikolai Axmacher
Journal:  Neuromolecular Med       Date:  2015-04-29       Impact factor: 3.843

5.  EEG low-resolution brain electromagnetic tomography (LORETA) in Huntington's disease.

Authors:  Annamaria Painold; Peter Anderer; Anna K Holl; Martin Letmaier; Gerda M Saletu-Zyhlarz; Bernd Saletu; Raphael M Bonelli
Journal:  J Neurol       Date:  2010-12-12       Impact factor: 4.849

6.  Comparative EEG mapping studies in Huntington's disease patients and controls.

Authors:  Annamaria Painold; Peter Anderer; Anna K Holl; Martin Letmaier; Gerda M Saletu-Zyhlarz; Bernd Saletu; Raphael M Bonelli
Journal:  J Neural Transm (Vienna)       Date:  2010-10-08       Impact factor: 3.575

Review 7.  The role of dopamine in Huntington's disease.

Authors:  Carlos Cepeda; Kerry P S Murphy; Martin Parent; Michael S Levine
Journal:  Prog Brain Res       Date:  2014       Impact factor: 2.453

8.  Quantitative Electroencephalographic Analysis Provides an Early-Stage Indicator of Disease Onset and Progression in the zQ175 Knock-In Mouse Model of Huntington's Disease.

Authors:  Simon P Fisher; Michael D Schwartz; Sarah Wurts-Black; Alexia M Thomas; Tsui-Ming Chen; Michael A Miller; Jeremiah B Palmerston; Thomas S Kilduff; Stephen R Morairty
Journal:  Sleep       Date:  2016-02-01       Impact factor: 5.849

9.  Dysregulation of corticostriatal ascorbate release and glutamate uptake in transgenic models of Huntington's disease.

Authors:  George V Rebec
Journal:  Antioxid Redox Signal       Date:  2013-06-19       Impact factor: 8.401

10.  QEEG Measures in Huntington's Disease: A Pilot Study.

Authors:  Aimee Hunter; Yvette Bordelon; Ian Cook; Andrew Leuchter
Journal:  PLoS Curr       Date:  2010-10-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.